Not logged inGenetic and immune landscape evolution in MMR-deficient colorectal cancer
Challoner, Benjamin R.; Woolston, Andrew; Lau, David; Buzzetti, Marta; Fong, Caroline; Barber, Louise J.; Anandappa, Gayathri; Crux, Richard; Assiotis, Ioannis; Fenwick, Kerry; Begum, Ruwaida; Begum, Dipa; Lund, Tom; Sivamanoharan, Nanna; Sansano, Harold B.; Domingo-Arada, Melissa; Tran, Amina; Pandha, Hardev; Church, David; Eccles, Bryony; Ellis, Richard; Falk, Stephen; Hill, Mark; Krell, Daniel; Murugaesu, Nirupa; Nolan, Luke; Potter, Vanessa; Saunders, Mark; Shiu, Kai-Keen; Guettler, Sebastian; Alexander, James L.; Lazare-Iglesias, Hector; Kinross, James; Murphy, Jamie; von Loga, Katharina; Cunningham, David; Chau, Ian; Starling, Naureen; Ruiz-Banobre, Juan; Dhillon, Tony; Gerlinger, Marco .png)
Share.png)
SavePD1 and LAG3 inhibition as second plus line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancerMencel, J.; Turkes, F.; Barber, L.; Challoner, B.; Buzzetti, M.; Tran, A.; Chen, H.; McCafferty, N.; Woolston, A.; Crux, R.; Rana, I.; Thomas, J.; Borja, V.; Begum, R.; Johnston, E.; Fotiadis, N.; Terlizzo, M.; Rao, S.; Chau, I.; Cunningham, D.; Gerlinger, M.; Starling, N. Share Save Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinomaGerlinger, Marco; Gordon, Anderley; Barber, Louise J.; Laliotis, Georgios; Athauda, Avani; Challoner, Benjamin; Woolston, Andrew; Mansukhani, Sonia; Dunstan, Matt; Petrou, Nikoletta; Khabra, Komel; Lazaro-Alcausi, Retchel; Crux, Richard; Borja, Victoria; Begum, Ruwaida; Rana, Isma; Palsuledesai, Charuta; Malhotra, Meenakshi; Liu, Minetta; Jurdi, Adham; Sharma, Shruti; Rao, Sheela; Kumar, Sacheen; Cunningham, David; Chau, Ian; Starling, Naureen; Chaudry, M. Asif Share Save Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancerChalloner, Benjamin R.; Woolston, Andrew; Lau, David; Buzzetti, Marta; Barber, Louise J.; Lund, Tom; Sansano, Harold B.; von Loga, Katharina; Lazare-Iglesias, Hector; Begum, Ruwaida; Crux, Richard; Cunningham, David; Chau, Ian; Starling, Naureen; Ruiz-Banobre, Juan; Dhillon, Tony; Gerlinger, Marco Share Save Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancerChalloner, Benjamin R.; Woolston, Andrew; Lau, David; Buzzetti, Marta; Barber, Louise J.; Lund, Tom; Sansano, Harold B.; von Loga, Katharina; Lazare-Iglesias, Hector; Begum, Ruwaida; Crux, Richard; Cunningham, David; Chau, Ian; Starling, Naureen; Ruiz-Banobre, Juan; Dhillon, Tony; Gerlinger, Marco Share Save Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised studyLau, David; Kalaitzaki, Eleftheria; Church, David N.; Pandha, Hardev; Tomlinson, Ian; Annels, Nicola; Gerlinger, Marco; Sclafani, Francesco; Smith, Gillian; Begum, Ruwaida; Crux, Richard; Gillbanks, Angela; Wordsworth, Sarah; Chau, Ian; Starling, Naureen; Cunningham, David; Dhillon, Tony Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
